Cargando…

Second Tier Molecular Genetic Testing in Newborn Screening for Pompe Disease: Landscape and Challenges

Pompe disease (PD) is screened by a two tier newborn screening (NBS) algorithm, the first tier of which is an enzymatic assay performed on newborn dried blood spots (DBS). As first tier enzymatic screening tests have false positive results, an immediate second tier test on the same sample is critica...

Descripción completa

Detalles Bibliográficos
Autores principales: Smith, Laurie D., Bainbridge, Matthew N., Parad, Richard B., Bhattacharjee, Arindam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7189780/
https://www.ncbi.nlm.nih.gov/pubmed/32352041
http://dx.doi.org/10.3390/ijns6020032
_version_ 1783527564558467072
author Smith, Laurie D.
Bainbridge, Matthew N.
Parad, Richard B.
Bhattacharjee, Arindam
author_facet Smith, Laurie D.
Bainbridge, Matthew N.
Parad, Richard B.
Bhattacharjee, Arindam
author_sort Smith, Laurie D.
collection PubMed
description Pompe disease (PD) is screened by a two tier newborn screening (NBS) algorithm, the first tier of which is an enzymatic assay performed on newborn dried blood spots (DBS). As first tier enzymatic screening tests have false positive results, an immediate second tier test on the same sample is critical in resolving newborn health status. Two methodologies have been proposed for second tier testing: (a) measurement of enzymatic activities such as of Creatine/Creatinine over alpha-glucosidase ratio, and (b) DNA sequencing (a molecular genetics approach), such as targeted next generation sequencing. (tNGS). In this review, we discuss the tNGS approach, as well as the challenges in providing second tier screening and follow-up care. While tNGS can predict genotype-phenotype effects when known, these advantages may be diminished when the variants are novel, of unknown significance or not discoverable by current test methodologies. Due to the fact that criticisms of screening algorithms that utilize tNGS are based on perceived complexities, including variant detection and interpretation, we clarify the actual limitations and present the rationale that supports optimizing a molecular genetic testing approach with tNGS. Second tier tNGS can benefit clinical decision-making through the use of the initial NBS DBS punch and rapid turn-around time methodology for tNGS, that includes copy number variant analysis, variant effect prediction, and variant ‘cut-off’ tools for the reduction of false positive results. The availability of DNA sequence data will contribute to the improved understanding of genotype-phenotype associations and application of treatment. The ultimate goal of second tier testing should enable the earliest possible diagnosis for the earliest initiation of the most effective clinical interventions in infants with PD.
format Online
Article
Text
id pubmed-7189780
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-71897802020-06-01 Second Tier Molecular Genetic Testing in Newborn Screening for Pompe Disease: Landscape and Challenges Smith, Laurie D. Bainbridge, Matthew N. Parad, Richard B. Bhattacharjee, Arindam Int J Neonatal Screen Review Pompe disease (PD) is screened by a two tier newborn screening (NBS) algorithm, the first tier of which is an enzymatic assay performed on newborn dried blood spots (DBS). As first tier enzymatic screening tests have false positive results, an immediate second tier test on the same sample is critical in resolving newborn health status. Two methodologies have been proposed for second tier testing: (a) measurement of enzymatic activities such as of Creatine/Creatinine over alpha-glucosidase ratio, and (b) DNA sequencing (a molecular genetics approach), such as targeted next generation sequencing. (tNGS). In this review, we discuss the tNGS approach, as well as the challenges in providing second tier screening and follow-up care. While tNGS can predict genotype-phenotype effects when known, these advantages may be diminished when the variants are novel, of unknown significance or not discoverable by current test methodologies. Due to the fact that criticisms of screening algorithms that utilize tNGS are based on perceived complexities, including variant detection and interpretation, we clarify the actual limitations and present the rationale that supports optimizing a molecular genetic testing approach with tNGS. Second tier tNGS can benefit clinical decision-making through the use of the initial NBS DBS punch and rapid turn-around time methodology for tNGS, that includes copy number variant analysis, variant effect prediction, and variant ‘cut-off’ tools for the reduction of false positive results. The availability of DNA sequence data will contribute to the improved understanding of genotype-phenotype associations and application of treatment. The ultimate goal of second tier testing should enable the earliest possible diagnosis for the earliest initiation of the most effective clinical interventions in infants with PD. MDPI 2020-04-05 /pmc/articles/PMC7189780/ /pubmed/32352041 http://dx.doi.org/10.3390/ijns6020032 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Smith, Laurie D.
Bainbridge, Matthew N.
Parad, Richard B.
Bhattacharjee, Arindam
Second Tier Molecular Genetic Testing in Newborn Screening for Pompe Disease: Landscape and Challenges
title Second Tier Molecular Genetic Testing in Newborn Screening for Pompe Disease: Landscape and Challenges
title_full Second Tier Molecular Genetic Testing in Newborn Screening for Pompe Disease: Landscape and Challenges
title_fullStr Second Tier Molecular Genetic Testing in Newborn Screening for Pompe Disease: Landscape and Challenges
title_full_unstemmed Second Tier Molecular Genetic Testing in Newborn Screening for Pompe Disease: Landscape and Challenges
title_short Second Tier Molecular Genetic Testing in Newborn Screening for Pompe Disease: Landscape and Challenges
title_sort second tier molecular genetic testing in newborn screening for pompe disease: landscape and challenges
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7189780/
https://www.ncbi.nlm.nih.gov/pubmed/32352041
http://dx.doi.org/10.3390/ijns6020032
work_keys_str_mv AT smithlauried secondtiermoleculargenetictestinginnewbornscreeningforpompediseaselandscapeandchallenges
AT bainbridgematthewn secondtiermoleculargenetictestinginnewbornscreeningforpompediseaselandscapeandchallenges
AT paradrichardb secondtiermoleculargenetictestinginnewbornscreeningforpompediseaselandscapeandchallenges
AT bhattacharjeearindam secondtiermoleculargenetictestinginnewbornscreeningforpompediseaselandscapeandchallenges